This trial will study the safety and efficacy of pembrolizumab in combination with investigational agents in people with anti-PD-1/PD-L1 refractory ES-SCLC who need second-line treatment. The trial will have two parts: a safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D), and an efficacy evaluation.
4 Primary · 2 Secondary · Reporting Duration: Up to approximately 60 months
Experimental Treatment
80 Total Participants · 4 Treatment Groups
Primary Treatment: coformulation favezelimab/pembrolizumab · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: